Sorrento Publishes Positive Initial Results of SOFUSA® Lymphatic Drug Delivery System in a Phase 1b Rheumatoid Arthritis Study Using Enbrel
23 août 2021 15h52 HE
|
Sorrento Therapeutics, Inc.
Rheumatoid Arthritis (RA) is one of many chronic autoimmune conditions affecting over 20 million people in the United States (NIH, 2017).Sofusa is a revolutionary technology which delivers biologic...